Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Carisma Therapeutics ( (CARM) ) has provided an update.
On October 9, 2025, Carisma Therapeutics Inc. received a delisting determination letter from Nasdaq due to noncompliance with listing rules, resulting in the suspension of its common stock trading on Nasdaq effective October 13, 2025. The company plans to list its stock on the OTCID market tier but acknowledges uncertainties regarding continued trading and market-making. Carisma Therapeutics intends to sell or monetize its remaining assets and wind down operations, with little expectation of cash distribution to stockholders.
The most recent analyst rating on (CARM) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Carisma Therapeutics stock, see the CARM Stock Forecast page.
Spark’s Take on CARM Stock
According to Spark, TipRanks’ AI Analyst, CARM is a Neutral.
Carisma Therapeutics’ overall stock score is primarily impacted by its poor financial performance and weak valuation. The company’s financial instability, negative equity, and liquidity issues are significant concerns. Technical analysis suggests a bearish trend, with some potential for stabilization. The lack of earnings call data and corporate events means these factors do not influence the score.
To see Spark’s full report on CARM stock, click here.
More about Carisma Therapeutics
Average Trading Volume: 8,589,480
Technical Sentiment Signal: Strong Sell
Current Market Cap: $10.97M
For detailed information about CARM stock, go to TipRanks’ Stock Analysis page.